Last reviewed · How we verify
MRG004A plus best supportive care
MRG004A is a bispecific antibody that simultaneously engages two immune checkpoints to enhance anti-tumor T cell responses.
MRG004A is a bispecific antibody that simultaneously engages two immune checkpoints to enhance anti-tumor T cell responses. Used for Advanced or metastatic solid tumors (Phase 3 indication under investigation).
At a glance
| Generic name | MRG004A plus best supportive care |
|---|---|
| Sponsor | Shanghai Miracogen Inc. |
| Drug class | Bispecific antibody |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
MRG004A functions as a bispecific antibody designed to target multiple immune regulatory pathways simultaneously, thereby overcoming immune evasion mechanisms in cancer. By engaging dual checkpoint targets, the drug aims to synergistically enhance T cell activation and proliferation while reducing immunosuppression in the tumor microenvironment. This approach is intended to improve clinical outcomes when combined with supportive care in advanced malignancies.
Approved indications
- Advanced or metastatic solid tumors (Phase 3 indication under investigation)
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MRG004A plus best supportive care CI brief — competitive landscape report
- MRG004A plus best supportive care updates RSS · CI watch RSS
- Shanghai Miracogen Inc. portfolio CI